VYVGART Achieves Primary Endpoint in Phase 3 Myositis Trial for argenx

summarizeSummary

argenx announced positive Phase 3 topline results for VYVGART Hytrulo in autoimmune myositis, meeting the primary endpoint with a 15.4-point improvement in Total Improvement Score.

check_boxKey Events · Product Development and Regulatory · ARGX

• Phase 3 ALKIVIA Trial Meets Primary Endpoint

  Efgartigimod showed a 15.4-point greater improvement in mean Total Improvement Score at Week 52 versus placebo (47.95 vs 32.56, p=0.0011) in the combined IMNM and DM population.

• First Positive Phase 3 Data in IMNM

  In the IMNM subtype, efgartigimod demonstrated a 14.8-point improvement over placebo (p=0.0048), marking the first Phase 3 study to show statistically significant benefit in this refractory disease with no approved therapy.

• Consistent Efficacy Across Subtypes

  DM patients showed a 14.5-point improvement (p=0.1093), not statistically significant in the smaller cohort but clinically meaningful, with all six core set measures favoring efgartigimod.

• Safety Profile Consistent with Prior Studies

  No new safety signals; adverse event rates were comparable to placebo, with injection site reactions more common in the efgartigimod arm (51.2% vs 21.3%).

auto_awesomeAnalysis · ARGX · Life Sciences

The ALKIVIA trial met its primary endpoint, showing a 15.4-point improvement in Total Improvement Score versus placebo (p=0.0011). This marks the first Phase 3 success in autoimmune myositis, a disease with no approved targeted therapies. The result validates efgartigimod's FcRn mechanism in a new rheumatology indication and supports a regulatory filing. With the stock trading near its 52-week high, this data could expand the market opportunity for VYVGART.